ALXA: Summary for Alexza Pharmaceuticals, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 4:58am EST - Canadian Markets open in 4 hours and 32 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Alexza Pharmaceuticals Inc. (ALXA)

On Feb 9: 2.6705 USD 0.00 (0.00%)

MORE ON ALXA

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Alexza Pharmaceuticals, Inc. (NGM:ALXA) Delayed quote data

Last Trade:	2.6705 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	2.6705
Open:	N/A
Bid:	2.44 x 100
Ask:	N/A
1y Target Est:	15.00

Day's Range:	N/A - N/A
52wk Range:	1.40 - 3.25
Volume:	0
Avg Vol (3m):	105,214
Market Cap:	137.84M
P/E (ttm):	N/A
EPS (ttm):	-1.627
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Add ALXA to Portfolio

Download Data

HEADLINES

•	Coverage initiated on Alexza Pharma by WBB Securities
	Briefing.com (Thu, Jan 28)

•	Alexza Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
	PRNewswire (Thu, Jan 28)

•	Alexza Takes Big Step Forward
	Zacks.com (Thu, Dec 17)

•	Alexza Pharmaceuticals Inc. Announces Submission of AZ-004 NDA Call scheduled for 8:30 am ET today
	CCBN (Tue, Dec 15)

•	JA Solar, Array BioPharma: Early Volume Plays
	at TheStreet.com (Tue, Dec 15)

•	ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events
	EDGAR Online (Mon, Dec 14)

•	Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA
	PRNewswire (Mon, Dec 14)

•	Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
	PRNewswire (Thu, Nov 19)

•	ALEXZA PHARMACEUTICALS INC. Financials
	EDGAR Online Financials (Sat, Nov 14)

•	Alexza Pharmaceuticals Inc. Earnings Call scheduled for 5:00 pm ET today
	CCBN (Mon, Nov 9)

•	ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition
	EDGAR Online (Mon, Nov 9)

More Headlines for ALXA...

ANALYST

EPS Est (next year) (Dec-07) :	N/A
EPS Est (in 2 years) (Dec-08) :	N/A
Avg Rec (current)*:	2.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Alexza Pharmaceuticals, Inc., a development stage company, focuses on the development and commercialization of products for the treatment of acute and intermittent conditions primarily in the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•